Society Letters

Comments on a Proposed Local Coverage Determination (LCD) on Implantable Continuous Glucose Monitors

September 25, 2020

To: Harry Feliciano, MD, MPH, Senior Medical Director, Palmetto GBA

"As further advances are made in this technology, it is important that more CGM options be made available to patients with diabetes. The Endocrine Society recommends CGM systems as the gold standard for managing type 1 diabetes, and the technology also can be useful for some people with type 2 diabetes. CGMs are also included in the American Diabetes Association’s (ADA) Standards of Medical Care for the treatment of patients with diabetes who require insulin. The Standards state that “when used properly, real-time continuous glucose monitors in conjunction with intensive insulin regiments is a useful tool to lower A1c in adults with type 1 diabetes who are not meeting glycemic targets.” The Standards also recommend that real-time CGMs be used on a daily basis if possible, for maximum benefit to the patient."

arrowRead the Full Letter 

Last Updated:
Take Action

Make Your Voice Heard

Take Action
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!